Table 2. Clinical pathological parameters and molecular characteristics of endometrial cancer patients with or without mutation/CNV of m6A regulatory genes.

		With mutation or/and CNV	Without mutation and CNV	P
Age	<=60	119	40	0.06834
	>60	224	47
Clinical stage	I	191	72	3.04E-05
	II	37	5
	III	94	10
	IV	24	0
Grade	G1	33	37	2.20E-16
	G2	62	28
	G3	243	21
	High Grade	8	1
Infiltration degree	< 50	152	55	2.17E-02
	>= 50	136	26
Lymphnode metastasis	Negative	120	40	0.06035
	Positive	207	42
Distal metastasis	Negative	177	50	0.3215
	Positive	150	32
POLE	WT	275	81	0.004894
	alteration	71	6
PTEN	WT	151	8	5.42E-09
	alteration	195	79
PIK3CA	WT	171	45	0.7918
	alteration	175	42
KRAS	WT	293	58	2.33E-04
	alteration	53	29
PIK3R1	WT	247	53	0.07808
	alteration	99	34
TP53	WT	171	84	3.70E-15
	alteration	175	3
FBXW7	WT	275	77	0.07572
	alteration	71	10
PPP2R1A	WT	271	85	4.73E-05

Note: With mutation or CNV: Cases have mutant or CNV or mutant+CNV, confirmed through TCGA database. Without mutant and CNV: Cases with neither mutant nor CNV, confirmed through TCGA database.